[1]刘旭辉,钱文浩,方　翔,等.不同剂量氯吡格雷对冠状动脉粥样硬化性心脏病患者凝血功能及炎症反应的影响[J].新乡医学院学报,2020,37(4):362-366.[doi:10.7683/xxyxyxb.2020.04.014]
　LIU Xuhui,QIAN Wenhao,FANG Xiang,et al.Effects of different doses of clopidogrel on coagulation function and inflammatory response in patients with coronary atherosclerosis heart disease[J].Journal of Xinxiang Medical University,2020,37(4):362-366.[doi:10.7683/xxyxyxb.2020.04.014]
点击复制

不同剂量氯吡格雷对冠状动脉粥样硬化性心脏病患者凝血功能及炎症反应的影响
分享到：

《新乡医学院学报》[ISSN:1004-7239/CN:41-1186/R]

卷:
37
期数:
2020年4
页码:
362-366
栏目:
临床研究
出版日期:
2020-04-05

文章信息/Info

Title:
Effects of different doses of clopidogrel on coagulation function and inflammatory response in patients with coronary atherosclerosis heart disease
作者:
刘旭辉1; 钱文浩2; 方　翔1; 王　勇1
（1.淮安市第二人民医院老年心血管科，江苏　 淮安　223002；2.徐州医科大学附属医院心血管内科，江苏 徐州 221000）
Author(s):
LIU Xuhui1; QIAN Wenhao2; FANG Xiang1; WANG Yong1
(1．Department of Geriatric Cardiology,the Second People′s Hospital of Huaian,Huaian 223002,Jiangsu Province,China;2.Department of Cardiovascular Medicine,the Affiliated Hospital of Xuzhou Medical University,Xuzhou 221000,Jiangsu Province,China)
关键词:
氯吡格雷; 冠状动脉粥样硬化性心脏病; 凝血功能; 炎症因子
Keywords:
clopidogrel; coronary atherosclerosis heart disease; coagulation function; inflammatory cytokines
分类号:
R541.4
DOI:
10.7683/xxyxyxb.2020.04.014
文献标志码:
A
摘要:
目的　探讨不同剂量氯吡格雷对冠状动脉粥样硬化性心脏病患者血小板膜糖蛋白、血小板聚集率及抑制率、凝血功能及炎症因子的影响。方法　选择2014年1月至2017年10月于淮安市第二人民医院就诊的96例CAHD患者为研究对象，将患者分为高剂量组（n=50）和常规剂量组(n=46)。2组患者均给予阿司匹林及调脂药物等常规对症治疗措施，在此基础上，常规剂量组患者口服氯吡格雷，首剂300 mg，随后每次75 mg维持治疗，每日1次，治疗7 d；高剂量组患者首剂口服氯吡格雷600 mg，随后每次150 mg维持治疗，每日1次，治疗7 d。采用酶联免疫吸附法测定2组患者治疗前及治疗7 d后血浆血小板活化分子α颗粒膜蛋白（CD62p）、可溶性白细胞分化抗原40配体（sCD40L）水平和血清单核细胞趋化因子-1（MCP-1）水平；流式细胞计数仪检测2组患者治疗前及治疗7 d后血浆溶酶体膜蛋白（CD61）、溶酶体完整膜蛋白（CD63）；使用全自动血凝分析仪检测2组患者治疗前及治疗7 d 后血浆纤维蛋白原（FIB）水平、活化部分凝血酶原时间（APTT）、凝血酶时间（TT）、凝血酶原时间（PT）；采用血小板聚集仪检测2组患者治疗前及用药24 h后血小板聚集率和血小板抑制率；免疫散射比浊法检测2组患者治疗前和治疗7 d后血清高敏C反应蛋白（hs-CRP）水平。结果　治疗前2组患者血小板膜糖蛋白CD61、CD63比率及血浆CD62p、sCD40L水平、血小板聚集率、血小板抑制率、FIB、APTT、PT、TT、血清MCP-1和hs-CRP水平比较差异均无统计学意义（P＞0.05）。2组患者治疗7 d后CD61、CD63比率及血浆CD62p、FIB水平、血清MCP-1、hs-CRP水平均显著低于治疗前（P＜0.05）；2组患者治疗7 d 后血浆sCD40L水平及APTT、PT、TT与治疗前比较差异均无统计学意义（P＞0.05）。治疗7 d后，高剂量组患者CD61、CD63比率及血浆CD62p、FIB水平和血清MCP-1、hs-CRP水平均显著低于常规剂量组（P＜0.05）；2组患者血浆sCD40L水平比较差异无统计学意义（P＞0.05）。2组患者服药后24 h血小板聚集率均显著低于治疗前，血小板抑制率均显著高于治疗前（P＜0.05）；服药后24 h,高剂量组患者血小板聚集率显著低于常规剂量组，血小板抑制率显著高于常规剂量组（P＜0.05）。高剂量组和常规剂量组患者不良反应发生率分别为6.00%（3/50）、2.17%（1/46），2组患者不良反应发生率比较差异无统计学意义（χ2=0.880，P＞0.05）。结论　高剂量氯吡格雷可有效降低血小板膜糖蛋白及炎症反应，降低机体对氯吡格雷的抵抗，明显改善患者凝血功能。
Abstract:
Objective　To investigate the effects of different doses of clopidogrel loads on platelet membrane glycoprotein,platelet aggregation rate and inhibition rate,coagulation function and inflammatory factors in patients with coronary atherosclerosis heart disease（CAHD）．Methods　Ninty-six CAHD patients in the Second People′s Hospital of Huaian from January 2014 to October 2017 were selected as the study objects.The patients were divided into high dose group (n=50) and conventional dose group (n=46)．All patients were given aspirin,lipid-regulating drugs and other conventional symptomatic treatment measures．Based on this,the patients in the conventional dose group took the clopidogrel orally,the first dose was 300 mg per day,followed by 75 mg per day maintenance treatment,once a day for 7 days;the patients in the high-dose group took orally clopidogrel 600 mg for the first dose,followed by 150 mg maintenance treatment,once a day for 7 days．The levels of platelet membrane glycoprotein of α grana membrane protein(CD62p),soluble CD40 ligand(sCD40L) and serum monocyte chemokine-1 (MCP-1) of patients in the two groups were measured by enzyme-linked immunosorbent assay before and 7 days after treatment;the plasma lysosomal membrane protein(CD61),lysosomal integral membrane protein(CD63) of patients in the two groups were measured by flow cytometer before and 7 days after treatment;the plasma fibrinogen (FIB),activated partial prothrombin time (APTT),prothrombin time (PT) and blood enzyme (TT) of patients in the two groups were measured by the automatic hemagglutination analyzer before and 7 days after treatment;the platelet aggregation rate,platelet inhibition rate of patients in the two groups were measured by the platelet aggregation instruments before and 24 hours after taking medicine;the serum high-sensitivity C-reactive protein (hs-CRP) level of patients in the two groups were measured by the immune scattering turbidimetry．Results　There was no significant difference in the platelet membrane glycoprotein CD61,CD63 ratio,the levels of plasma CD62p and sCD40L,platelet aggregation rate,platelet inhibition rate,FIB,APTT,PT,TT,serum levels of MCP-1 and hs-CRP between the two groups before treatments (P>0.05)．The CD61 and CD63 ratio,the levels of plasma CD62p and FIB,the serum levels of MCP-1,hs-CRP of patients in the two groups at 7 d after treatment were significantly lower than those before treatment (P<0.05);there was no significantly difference in the plasma level of sCD40L and APTT,PT,TT before treatment and 7 d after treatment in the two groups（P＞0.05）．After 7 days of treatment,the CD61 and CD63 ratio,the levels of plasma CD62p and FIB,the serum levels of MCP-1,hs-CRP of patients in high dose group were significantly lower than those in the conventional dose group (P<0.05);there was no significantly difference in the plasma level of sCD40L between the two groups（P＞0.05）.Compared with before treatment,the platelet inhibition rate of patients in the two groups was decreased,and the platelet aggregation rate of patients in the two groups was increased at 24 hours after taking medicine (P<0.05);At 24 hours after taking medicine,the platelet inhibition rate of patients in the high dose group was higher than that in the conventional dose group(P<0.05),the platelet aggregation rate of patients in the high dose group was lower than that in the conventional dose group(P<0.05) ．The incidence of adverse reaction of patients was 6.00%(3/50),2.17%(1/46);there was no statistic difference in the incidence of adverse reaction between the two groups(χ2　=0.880,P＞0.05)Conclusion　High dose clopidogrel can effectively reduce the platelet membrane glycoprotein and inflammatory response,reduce the resistance of the body to clopidogrel,and significantly improve the coagulation function of patients.

参考文献/References:

［1］　LYU Y,JIANG X,DAI W．The roles of a novel inflammatory neopterin in subjects with coronary atherosclerotic heart disease［J］.Int Immunopharmacol,2015,24(2):169-172.
［2］　ZHANG Y,HUANG J,YANG X,et al．Altered expression of TXNIP in the peripheral leukocytes of patients with coronary atherosclerotic heart disease［J］．Medicine,2017,96(49):e9108.
［3］　DAI W,LI Y,LV Y N,et al．The roles of a novel anti-inflammatory factor,milk fat globule-epidermal growth factor 8,in patients with coronary atherosclerotic heart disease［J］．Atherosclerosis,2014,233(2):661-665.
［4］　BROWN R A,GYH L,VARMA C,et al．Impact of Mon2 monocyte-platelet aggregates in humancoronary artery disease［J］．Eur J Clin Invest,2018,48(5):e12911.
［5］　YI X,LIN J,ZHOU Q,et al．Clopidogrel Resistance increases rate of recurrent stroke and other vascular events in chinese population［J］．J Stroke Cerebrovasc Dis,2016,25(5):1222-1228.
［6］　ANTMAN E M,ANBE D T,ARMSTRONG P W,et al．ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction——executive summary:a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1999 ［J］．J Am Coll Cardiol,2004,44(3):671-719.
［7］　胡盛寿,高润霖,刘力生,等.《中国心血管病报告2018》概要［J］.中国循环杂志,2019,34(03):209-220.
［8］　胡晨鸣,刘继洪,吴瑜.耳穴埋豆+复方丹参滴丸对稳定性心绞痛患者血小板功能、炎症反应及蛋白酶表达的影响［J］.海南医学院学报,2018,24(13):1226-1229.
［9］　SINNING J M,JANSEN F,HAMMERSTINGL C,et al．Circulating microparticles decrease after cardiac stress in patients with significant coronary artery stenosis［J］．Clin Cardiol,2016,39(10):570-577.
［10］　梁戎,张园.阿司匹林与氯吡格雷双联抗血小板治疗对老年低危不稳定型心绞痛患者的疗效及安全性［J］.实用老年医学,2016,30(2):125-127，131.
［11］　SU J,YU Q,ZHU H,et al．The risk of clopidogrel resistance is associated with ABCB1 polymorphisms but not promoter methylation in a Chinese Han population［J］．Plos One,2017,12(3):e0174511.
［12］　WORKING GROUP OF THE SEC ON THE 2013 ESC GUIDELINES ON THE MANAGEMENT OF STABLE CORONARY ARTERY DISEASE，REVIEWERS FOR THE 2013 ESC GUIDELINES ON THE MANAGEMENT OF STABLE CORONARY ARTERY DISEASE，SEC GUIDELINES COMMITTEE．Comments on the 2013 ESC guidelines on the management of stable coronary artery disease［J］．Rev Esp Cardiol (Engl Ed),2014,67(2):80-86.
［13］　颜程光,王俊谊,黄贵奇,等.氯吡格雷对PCI患者血小板功能状态及血流变的影响［J］.心血管康复医学杂志,2014,23(6):671-674.
［14］　吴志福．不同维持量氯吡格雷对急性冠状动脉综合征患者血小板膜糖蛋白、血小板聚集功能及氯吡格雷抵抗率的影响［J］．广西医学,2016,38(9):1304-1305,1314.
［15］　FONG S W,FEW L L,SEE TOO W C,et al．Systemic and coronary levels of CRP,MPO,sCD40L and PlGF in patients with coronary artery disease［J］．BMC Res Notes,2015,8(1):679.
［16］　MURAKAMI T,KOMIYAMA Y,MASUDA M,et al．Flow cytometric analysis of platelet activation markers CD62P and CD63 in patients with coronary artery disease［J］．Eur J Clin Invest,2015,26(11):996-1003.
［17］　张波涛,张学虎,马列,等．不同剂量氯吡格雷对冠状动脉粥样硬化性心脏病患者血清CD62p水平的影响［J］．中国综合临床,2014,30(4):363-366.
［18］　马巧红,徐清斌,张波涛,等.不同剂量氯吡格雷对冠心病患者血清sCD40L水平的影响［J］.广东医学,2014,35(7):1102-1104.
［19］　杨蔚,赵婕青,丁小英．氯吡格雷联合阿托伐他汀治疗脑梗死对患者血液流变学、炎症反应及凝血功能的影响［J］．海南医学院学报,2018,24(3):409-412，416.
［20］　马志刚,闫立荣,唐澍.不同剂量阿托伐他汀联合氯吡格雷治疗脑梗死的疗效及对凝血功能和hs-CRP的影响［J］.广西医科大学学报,2017,34(3):398-402.

相似文献/References:

[1]吕风华,张素荣,张跃光,等.冠状动脉粥样硬化性心脏病合并充血性心力衰竭患者血浆脑钠肽水平的检测[J].新乡医学院学报,2007,24(06):581.
[2]廖燕.老年冠状动脉粥样硬化性心脏病患者心功能与肺动脉压和心电指标的关系[J].新乡医学院学报,2012,29(09):696.
[3]郭鹏,李继红.不同类型冠状动脉粥样硬化性心脏病患者血浆D-二聚体和纤维蛋白原水平变化[J].新乡医学院学报,2012,29(09):698.
[4]李永锋,许志强,韩 鹏,等.冠状动脉粥样硬化性心脏病合并阻塞性睡眠呼吸暂停低通气综合征的临床分析 [J].新乡医学院学报,2012,29(10):784.
[5]张 立１,艾 妮. 氯吡格雷联合阿托伐他汀钙治疗短暂性脑缺血发作疗效观察 [J].新乡医学院学报,2015,32(02):175.[doi:10.7683/xxyxyxb.2015.02.023]
[6]舒　毅,陈幼萍,曾春平,等. ２型糖尿病合并冠状动脉粥样硬化性心脏病患者下肢血管病变相关因素分析[J].新乡医学院学报,2015,32(08):785.
[7]杨亚明,赵国安,冯春瑜,等.冠状动脉粥样硬化性心脏病患者的血脂代谢机制及药物治疗研究进展[J].新乡医学院学报,2021,38(10):996.[doi:10.7683/xxyxyxb.2021.10.020]
[8]许明发,王帅飞,苏国宝,等.不同血运重建方式治疗冠状动脉粥样硬化性心脏病合并左心室功能不全的早期疗效比较[J].新乡医学院学报,2018,35(11):1018.[doi:10.7683/xxyxyxb.2018.11.018]
　XU Ming-fa,WANG Shuai-fei,SU Guo-bao,et al.Comparison of early outcomes of two kinds of revascularization on the patients with coronary heart disease complicated with left ventricular dysfunction[J].Journal of Xinxiang Medical University,2018,35(4):1018.[doi:10.7683/xxyxyxb.2018.11.018]
[9]欧红萍,李 彬,周凤勤.颈动脉超声检查联合血清超敏C 反应蛋白水平检测在冠状动脉粥样硬化性心脏病诊断中的应用[J].新乡医学院学报,2014,31(10):825.[doi:10.7683/xxyxyxb.2014.10.016]
[10]王　一.冠状动脉粥样硬化性心脏病合并二尖瓣疾病和心房颤动患者同期行冠状动脉搭桥联合二尖瓣置换术和双极射频消融术疗效观察[J].新乡医学院学报,2019,36(2):155.[doi:10.7683/xxyxyxb.2019.02.013]
　WANG Yi.Clinical effect of coronary artery bypass grafting and mitral valve replacement and bipolar radiofrequency ablation on the patients with coronary atherosclerotic heart disease combined with mitral valve disease and atrial fibrillation[J].Journal of Xinxiang Medical University,2019,36(4):155.[doi:10.7683/xxyxyxb.2019.02.013]

更新日期/Last Update: 2020-04-05